Drug Profile
YE NEO 001
Alternative Names: Neoepitope yeast vaccine - NantBioScience; YE-NEO 001Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator NantBioScience
- Class Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in USA (Parenteral, Suspension)
- 10 Aug 2018 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in USA (Parenteral) (NCT03552718)
- 20 Jun 2018 NantBioScience plans a phase I QUILT-2.025 trial for Solid tumours (Second-line therapy or greater) in USA (NCT03552718)